Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.

Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova-Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S.

Cancer Res. 2019 Aug 15;79(16):4026-4041. doi: 10.1158/0008-5472.CAN-18-3521. Epub 2019 Jun 14.

PMID:
31201162
2.

Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.

Guan X, Luo L, Begum G, Kohanbash G, Song Q, Rao A, Amankulor N, Sun B, Sun D, Jia W.

J Exp Clin Cancer Res. 2018 Oct 17;37(1):255. doi: 10.1186/s13046-018-0923-z.

3.

Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.

Guan X, Hasan MN, Begum G, Kohanbash G, Carney KE, Pigott VM, Persson AI, Castro MG, Jia W, Sun D.

Cell Death Dis. 2018 Sep 27;9(10):1010. doi: 10.1038/s41419-018-1062-3.

4.

Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.

Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G.

JCI Insight. 2018 Apr 5;3(7). pii: 98791. doi: 10.1172/jci.insight.98791. eCollection 2018 Apr 5.

5.

Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.

Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A.

Genome Biol. 2017 Dec 20;18(1):234. doi: 10.1186/s13059-017-1362-4.

6.

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H.

J Exp Med. 2018 Jan 2;215(1):141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.

7.

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H.

J Clin Invest. 2017 Apr 3;127(4):1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.

8.

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.

Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK.

Oncogene. 2017 Jun 29;36(26):3749-3759. doi: 10.1038/onc.2017.1. Epub 2017 Feb 20.

9.

Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas.

Müller S, Liu SJ, Di Lullo E, Malatesta M, Pollen AA, Nowakowski TJ, Kohanbash G, Aghi M, Kriegstein AR, Lim DA, Diaz A.

Mol Syst Biol. 2016 Nov 25;12(11):889. doi: 10.15252/msb.20166969.

10.

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.

Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H.

J Neurooncol. 2016 Dec;130(3):543-552. Epub 2016 Sep 13.

11.

Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.

Lal S, Peng KW, Steele MB, Jenks N, Ma H, Kohanbash G, Phillips JJ, Raffel C.

Hum Gene Ther Clin Dev. 2016 Dec;27(4):145-151. Epub 2016 Sep 7.

PMID:
27604429
12.

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.

Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM.

Sci Rep. 2016 Aug 10;6:31397. doi: 10.1038/srep31397.

13.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

14.

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N.

Neuro Oncol. 2016 Oct;18(10):1402-12. doi: 10.1093/neuonc/now061. Epub 2016 Apr 25.

15.

Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas.

Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H.

Oncoimmunology. 2015 May 26;4(11):e1047581. eCollection 2015 Nov.

16.

Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.

Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H.

Biochem Biophys Res Commun. 2015 Mar 13;458(3):549-554. doi: 10.1016/j.bbrc.2015.02.003. Epub 2015 Feb 10.

17.

Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS.

Clin Cancer Res. 2015 Jan 15;21(2):286-94. doi: 10.1158/1078-0432.CCR-14-1790. Epub 2014 Nov 25.

18.

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H.

Cancer Res. 2013 Nov 1;73(21):6413-23. doi: 10.1158/0008-5472.CAN-12-4124. Epub 2013 Sep 12.

19.

Premetastatic soil and prevention of breast cancer brain metastasis.

Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H.

Neuro Oncol. 2013 Jul;15(7):891-903. doi: 10.1093/neuonc/not031. Epub 2013 Apr 17.

20.

Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.

Kohanbash G, Okada H.

Immunol Invest. 2012;41(6-7):658-79. doi: 10.3109/08820139.2012.689591. Review.

PMID:
23017140
21.

Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma.

Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H.

Oncoimmunology. 2012 Jul 1;1(4):487-492.

22.

MicroRNAs and STAT interplay.

Kohanbash G, Okada H.

Semin Cancer Biol. 2012 Feb;22(1):70-5. doi: 10.1016/j.semcancer.2011.12.010. Epub 2011 Dec 24. Review.

23.

COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.

Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H.

Cancer Res. 2011 Apr 1;71(7):2664-74. doi: 10.1158/0008-5472.CAN-10-3055. Epub 2011 Feb 15.

24.

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS.

J Clin Oncol. 2011 Jan 20;29(3):330-6. doi: 10.1200/JCO.2010.30.7744. Epub 2010 Dec 13.

25.

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.

Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H.

Cancer Immunol Immunother. 2010 Sep;59(9):1401-9. doi: 10.1007/s00262-010-0876-3. Epub 2010 Jun 12.

26.

Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.

Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H.

Clin Cancer Res. 2010 Jul 1;16(13):3409-19. doi: 10.1158/1078-0432.CCR-10-0644. Epub 2010 May 14.

27.

miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.

Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H.

J Transl Med. 2010 Feb 18;8:17. doi: 10.1186/1479-5876-8-17.

28.

MicroRNAs in immune regulation--opportunities for cancer immunotherapy.

Okada H, Kohanbash G, Lotze MT.

Int J Biochem Cell Biol. 2010 Aug;42(8):1256-61. doi: 10.1016/j.biocel.2010.02.002. Epub 2010 Feb 6. Review.

29.

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.

Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H.

Clin Cancer Res. 2009 Nov 1;15(21):6551-9. doi: 10.1158/1078-0432.CCR-09-1067. Epub 2009 Oct 27.

30.

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ.

J Immunother. 2009 Oct;32(8):793-802. doi: 10.1097/CJI.0b013e3181acec1e.

31.

Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.

Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H.

Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10746-51. doi: 10.1073/pnas.0811817106. Epub 2009 Jun 11.

32.

Immunotherapeutic approaches for glioma.

Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M.

Crit Rev Immunol. 2009;29(1):1-42. Review.

33.

Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.

Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H.

Cancer Res. 2009 Feb 15;69(4):1587-95. doi: 10.1158/0008-5472.CAN-08-2915. Epub 2009 Feb 3. Erratum in: Cancer Res. 2010 Aug 15;70(16):6683.

34.

Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.

Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF.

J Neurooncol. 2008 Jul;88(3):245-50. doi: 10.1007/s11060-008-9566-9. Epub 2008 Mar 7.

Supplemental Content

Loading ...
Support Center